Genmab — April 2018
-
https://www.fiercebiotech.com/biotech/j-j-says-it-has-15-more-to-splash-r-d-thanks-to-tax-cuts-so-will-we-see-more-pipeline-plays Her lidt om J&J's R&D beholdning for de næste 4 år. De kunne snildt købe Genmab til denne lave pris, de har rigeligt med penge ser det ud til, hvilket ikke kommer bag på nogen eller hur?
-
-
mon Jan Har nosser til en lille opjustering i.f.b med Q1 regnskabet 8 Maj. Formodet det var en konservativ guiding han kommer i Februar og nu +2 mdr senere har der vaeret tid til at regne yderligere paa tallene. Kunne vaere herligt at faa shorterne til at traekke stikket.
-
God morgen.

-
God morgen.
Jeg har ikke fået salgstal. -
God morgen

-
https://twitter.com/DrKantor/status/989020060579704832 - Poster : Ofatumumab (subcutaneous anti-CD20) effects on white blood cells in mice vs. IV version
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind